Results 91 to 100 of about 2,847,915 (169)

Lipid nanoparticle-encapsulated DOCK11-siRNA efficiently reduces hepatitis B virus cccDNA level in infected mice

Molecular Therapy: Methods & Clinical Development
The hepatitis B virus (HBV) infects many people worldwide. As HBV infection frequently leads to liver fibrosis and carcinogenesis, developing anti-HBV therapeutic drugs is urgent.
Hikari Okada, Takeharu Sakamoto, Kouki Nio, Yingyi Li, Kazuyuki Kuroki, Saiho Sugimoto, Tetsuro Shimakami, Nobuhide Doi, Masao Honda, Motoharu Seiki, Shuichi Kaneko, Taro Yamashita   +11 more
doaj   +1 more source

Profound reduction of HBV covalently closed circular DNA with long-term nucleoside/tide analogue therapy

, 2014
BACKGROUND: Long-term nucleoside/tide analogue (NA) treatment suppresses serum HBV DNA to undetectable levels in a majority of patients. We aimed to investigate the effect of longterm NA on the suppression of covalently closed circular DNA (cccDNA) and ...
Lai, CL, Wong, DKH, Seto, WK, Yuen, JCH, Ip, P, Wu, CH, Huang, FY, Yuen, MF, Ngai, V, Kopaniszen, M, Fung, J, Lee, BP, Cullaro, G, Cheng, C   +13 more
core   +1 more source

Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection

, 2005
OBJECTIVE: To determine the effect of 1-yr lamivudine treatment on serum covalently closed-circular DNA (cccDNA) level. PATIENTS AND METHOD: Serum total HBV DNA and cccDNA levels at baseline, week 24, and week 52 were measured in 82 lamivudine-treated ...
Wong, BCY, Yuan, HJ, Sum, SSM, Lai, CL, Chan, AOO, Wong, DKH, Yuen, JCH, Yuen, MF   +7 more
core   +1 more source

Episomal and integrated hepatitis B transcriptome mapping uncovers heterogeneity with the potential for drug-resistance

Nature Communications
Hepatitis B virus (HBV) is a small DNA virus that establishes chronic infection and drives progressive liver disease and cancer; presenting a global health problem with more than 250 million infections.
James M. Harris, James Lok, Nadina Wand, Andrea Magri, Senko Tsukuda, Yanxia Wu, Esther Ng, Daisy Jennings, Badran Elshenawy, Peter Balfe, Jane A. McKeating   +10 more
doaj   +1 more source

Chronic Hepatitis B Genotype C Mouse Model with Persistent Covalently Closed Circular DNA

Hepatitis B virus (HBV) can cause chronic infections, significantly increasing the risk of death from cirrhosis and hepatocellular carcinoma (HCC). A key player in chronic HBV infection is covalently closed circular DNA (cccDNA), a stable episomal form ...
Songmee Bae, Juhee Won, Kyun-Hwan Kim, Wonhee Hur, Deok-Hwa Seo, Seung-Kew Yoon, Ji-Won Han, Pil-Soo Sung   +7 more
core   +1 more source

Concerted action of activation-induced cytidine deaminase and uracil-DNA glycosylase reduces covalently closed circular DNA of duck hepatitis B virus

Covalently closed circular DNA (cccDNA) forms a template for the replication of hepatitis B virus (HBV) and duck HBV (DHBV). Recent studies suggest that activation-induced cytidine deaminase (AID) functions in innate immunity, although its molecular ...
Chowdhury, Sajeda, Koura, Miki, Muramatsu, Masamichi, Kitamura, Kouichi, Simadu, Miyuki   +4 more
core  

Host 3’ flap endonuclease Mus81 plays a critical role in trimming the terminal redundancy of hepatitis B virus relaxed circular DNA during covalently closed circular DNA formation

Hepatitis B virus (HBV) relaxed circular DNA (rcDNA) possesses an 8-9 nucleotide-long terminal redundancy (TR, or r) on the negative (-) strand DNA derived from the reverse transcription of viral pregenomic RNA (pgRNA).
Liu, Cheng-Der, Sun, Ning, Zhang, Hu, Long, Quanxin, Marchetti, Alexander L., Guo, Haitao, Liu, Yuanjie   +6 more
core   +1 more source

One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels

, 2006
Entecavir and lamivudine are potent nucleoside analogues that can suppress hepatitis B virus (HBV) replication. However, the effects of these two antiviral agents on intrahepatic total HBV DNA and covalently closed circular DNA (cccDNA) are not known. In
Ngai, VWS, Fung, J, Lai, CL, Wong, DKH, Yuen, MF   +4 more
core  

Targeting Covalently Closed Circular DNA (cccDNA): Emerging Therapeutic Strategies Toward a Functional Cure for Chronic Hepatitis B

Chronic HBV won't be resolved in the immediate future. Almost 300 million individuals live with it [1], as well as it causes roughly 820,000 deaths annually [1]—mainly due to conditions such as cirrhosis, liver failure, or liver cancer. The usual therapies, such as nucleos(t)ide analogues and pegylated interferon-alpha, effectively manage the ...
openaire   +1 more source

Chromatin Accessibility-Guided Targeting Identifies Structurally Constrained Regions in HBV cccDNA and Suppresses Viral Replication. [PDF]

Int J Mol Sci
Kong L, Iwabuchi S, Li YY, Murai K, Korai R, Kawaguchi K, Nio K, Imafuku T, Shimakami T, Yamashita T, Tajima A, Suzuki Y, Honda M, Hashimoto S.   +13 more
europepmc   +1 more source